{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:34:05Z","timestamp":1792510445835,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2024,7,16]]},"abstract":"<jats:sec id=\"jah39792-sec-0001\" xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Results from ATTR\u2010ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy)\u00a0indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR\u2010CA). However, real\u2010world data supporting these findings are scarce. Thus, we sought to characterize the clinical outcome of patients with ATTR\u2010CA treated with tafamidis in a real\u2010world setting and assess the prognostic role of the New York Heart Association (NYHA) classification.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec id=\"jah39792-sec-0002\" xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">We conducted a retrospective observational study, enrolling a consecutive sample of patients with ATTR\u2010CA (wild\u2010type or variant) treated with tafamidis. Clinical outcome was tracked through follow\u2010up visits or phone calls. Primary outcomes were death and major adverse cardiac events (MACE), a composite end point of death and hospitalizations for acute cardiac decompensation, myocardial infarction, severe arrythmias, or stroke. Kaplan\u2010Meier analysis estimated overall and MACE\u2010free survival including NYHA subgroups (NYHA I\/II versus NYHA III).<\/jats:p>\n            <jats:p xml:lang=\"en\">\n              One hundred sixty\u2010seven patients with ATTR\u2010CA (94.6% wild\u2010type) were enrolled and followed for a median of 539 [323\u2013869] days. Median overall survival was not reached. Estimated 1\u2010year, 2\u2010year, and 5\u2010year overall survival among the whole cohort was 93.5%, 85.9%, and 70.2%, respectively. Overall survival was higher in the NYHA I\/II subgroup (\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              =0.002). Median MACE\u2010free survival time was 1082 (95% CI, 962\u20131202) days. MACE\u2010free survival was higher in the NYHA I\/II subgroup (\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              &lt;0.001). With respective hazard ratios of 5.85 (95% CI, 1.48\u201323.18;\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              =0.012) and 3.95 (95% CI, 1.99\u20137.84;\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              &lt;0.001), NYHA III was an independent predictor of death and MACE.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec id=\"jah39792-sec-0003\" xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Treatment of ATTR\u2010CA with tafamidis led to substantial improvements of clinical outcome. NYHA classification at treatment initiation is a reliable tool to provide patients with individualized prognostic information.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.123.033478","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T10:41:33Z","timestamp":1720003293000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real\u2010World Data"],"prefix":"10.1161","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6281-9754","authenticated-orcid":false,"given":"Maximilian Leo","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5130-2845","authenticated-orcid":false,"given":"Ekaterina","family":"Latinova","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-0347","authenticated-orcid":false,"given":"Anna","family":"Brand","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8455-3750","authenticated-orcid":false,"given":"Isabel","family":"Mattig","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-8007","authenticated-orcid":false,"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-5004","authenticated-orcid":false,"given":"Daniel","family":"Messroghli","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6013-0072","authenticated-orcid":false,"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9","place":["Berlin, Germany"]},{"name":"Department of Neurology and Experimental Neurology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-3203","authenticated-orcid":false,"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3811-7920","authenticated-orcid":false,"given":"Bettina","family":"Heidecker","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9","place":["Berlin, Germany"]},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1695"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13541"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"e_1_3_2_8_2","unstructured":"Vyndaqel: EPAR \u2010 Product Information CHMP 2011 European Medicines Agency https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/vyndaqel\u2010epar\u2010product\u2010information_en.pdf Last updated: September 2023 Last accessed: 22.03.24"},{"key":"e_1_3_2_9_2","unstructured":"Highlights of Prescribing Information for VYNDAQEL and VYNDAMAX 2023 Pfizer Inc. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=11685 Last updated: October 2023 Last accessed: 22.03.24"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2974"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102172"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2589"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101358"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14380"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.007"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.123.033478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:50:38Z","timestamp":1747302638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.123.033478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":18,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,16]]}},"alternative-id":["10.1161\/JAHA.123.033478"],"URL":"https:\/\/doi.org\/10.1161\/jaha.123.033478","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"2024-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e033478"}}